[1] SEARLE R D,BENNETT M I,JOHNSON M I,et al.Clebopride:Abdominal dyskinesia treated with transcutaneous electrical nerve stimulation:case report[J].Palliative Medicine,2008,22(7):878-879.
[2] MARANO M,BIASE di L,SALOMONE G,et al.The clinical course of a drug-induced acute dystonic reaction in the emergency room[J].Tremor?Other?Hyperkinet Mov,2016,6:436.
[3] LIN L.Clebopride[M].Handbook of Metabolic Pathways of Xenobiotics.John Wiley&Sons,Ltd,2014.
[4] JAMSHIDI N,DAWSON A.The hot patient: acute drug-induced hyperthermia[J].Aust Prescr,2019,42(1):24-28.
[5] QUIK M,BORDIA T,ZHANG D,et al.Nicotine and Nicotinic Receptor Drugs:Potential for Parkinson’s Disease and Drug-Induced Movement Disorders[J].International Review of Neurobiology,2015,124:247-271.
[6] CORNETT E M,NOVITCH M,KAYE A D,et al.Medication-induced tardive dyskinesia: a review and update[J].Ochsner J,2017,17(2):162-174.
[7] GURRERA R J,MORTILLARO G,VELAMOOR V,et al.A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome[J].J Clin Psychopharmacol,2017,37(1):67-71.
[8] PIERRE R B,JUDIT H,VANESSA F,et al.Movement disorders emergencies[J].Revue Médicale Suisse,2018,14(604):888-891.
[9] PARK H W,KWAK J R,LEE J S.Clinical characteristics of acute drug-induced dystonia in pediatric patients[J].Clinical &Experimental Emergency Medicine,2017,4(3):133-137.
[10] NIEMANN N,JANKOVIC J.Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors[J].Drugs,2018,78(5):525-541.
[11] MORGAN J C,KUREK J A,DAVIS J L,et al.Insights into Pathophysiology from Medication-induced Tremor[J].Tremor Other Hyperkinet Mov(N Y),2017,7:442. |
